贝伐单抗联合吉西他滨和顺铂联合化疗治疗晚期非小细胞肺癌的临床疗效
Clinical efficacy of bevacizumab combined with gemcitabine and cisplatin combination chemotherapy in the treatment of advanced non-small cell lung cancer.
作者信息
Duan Jianchun, Yang Zhenhua, Liu Dingyuan, Shi Yunfei
机构信息
Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, PR China.
出版信息
J BUON. 2018 Sep-Oct;23(5):1402-1406.
PURPOSE
To investigate the clinical efficacy of bevacizumab combined with gemcitabine and cisplatin (GP) combination chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).
METHODS
A total of 186 patients with advanced NSCLC who were admitted to the First Affiliated Hospital of Kunming Medical University from October 2013 to June 2016 were randomly divided into control group and observation group, with 93 cases in each group. Patients in the control group were treated with GP chemotherapy, while patients in observation group were treated with intravenous infusion of bevacizumab combined with GP chemotherapy. Treatment was administered for 3 courses, every 3 weeks. After treatment, clinical efficacy, tumor markers levels (CEA and CYFRA21-1), serum vascular endothelial growth factor (VEGF) levels and adverse reactions were compared between two groups.
RESULTS
After treatment, the total effective rate and disease control rate in the control group were 40.86% and 70.97%, respectively, while the total effective rate and disease control rate in the observation group were 70.97% and 90.32% respectively, (p<0.05). After treatment, the levels of CEA, CYFRA21-1 and serum VEGF in both groups were significantly lower than those before treatment (p<0.05), and decreases were more significant in the observation group than in the control group (p<0.05). The overall 1-, 3- and 5-year survival rates were 52.69% (49 cases), 36.56% (34 cases) and 25.81% (24 cases) for the observation group, and 43.01% (40 cases), 27.96% (26 cases) and 15.05 % (14 cases) for the control group. Overall survival rate in the observation group was significantly higher than the one in the control group (p<0.05).
CONCLUSION
The combination of bevacizumab plus GP chemotherapy for advanced NSCLC can improve serum tumor markers and clinical efficacy, thus prolonging the long-term survival of patients. It is worthy of clinical application.
目的
探讨贝伐单抗联合吉西他滨和顺铂（GP）方案化疗治疗晚期非小细胞肺癌（NSCLC）的临床疗效。
方法
选取2013年10月至2016年6月昆明医科大学第一附属医院收治的186例晚期NSCLC患者，随机分为对照组和观察组，每组93例。对照组采用GP方案化疗，观察组采用静脉输注贝伐单抗联合GP方案化疗。每3周为1个疗程，共治疗3个疗程。治疗后，比较两组患者的临床疗效、肿瘤标志物水平（癌胚抗原CEA和细胞角蛋白19片段CYFRA21-1）、血清血管内皮生长因子（VEGF）水平及不良反应。
结果
治疗后，对照组的总有效率和疾病控制率分别为40.86%和70.97%，观察组的总有效率和疾病控制率分别为70.97%和90.32%，差异有统计学意义（p<0.05）。治疗后，两组患者的CEA、CYFRA21-1及血清VEGF水平均较治疗前显著降低（p<0.05），且观察组降低更明显（p<0.05）。观察组的1年、3年和5年总生存率分别为52.69%（49例）、36.56%（34例）和25.81%（24例），对照组分别为43.01%（40例）、27.96%（26例）和15.05%（14例）。观察组的总生存率显著高于对照组（p<0.05）。
结论
贝伐单抗联合GP方案化疗治疗晚期NSCLC可改善血清肿瘤标志物水平及临床疗效，从而延长患者的长期生存，值得临床应用。
Zotero 插件